Skip to main content
Heritage Bio Labs · Research use only
Heritage Bio Labs

Heritage Bio Labs

Research Library

Explore 411 articles about peptides, research compounds and related topics, with links to the original studies.

Browse by productGeneral topics

Find articles

All articles

Showing 361–372 of 411 articles

  • Explore study findings

    What an MRI showed about liver fat in SYNCHRONIZE-MASLD

    Survodutide is an investigational glucagon and GLP-1 receptor agonist peptide. A phase 3 study reported in 2026 asked whether it changed liver fat and body weight in adults with obesity and at-risk metabolic dysfunction-associated steatotic liver disease, or MASLD.

    Survodutide2 sources (2024, 2026)

  • Understand the science

    How SYNCHRONIZE-1 counted average weight change and response rates

    Survodutide is an investigational peptide that activates GLP-1 and glucagon receptors. SYNCHRONIZE-1 tested it in adults with obesity or overweight and a related complication who did not have diabetes.

    Survodutide1 source (2026)

  • Explore study findings

    Why the earlier MASH trial examined liver tissue directly

    Survodutide is an investigational peptide with activity at the glucagon and GLP-1 receptors. The older direct study for the biopsy question was a phase 2 trial in adults with confirmed metabolic dysfunction-associated steatohepatitis, or MASH, and varying degrees of scarring.

    Survodutide2 sources (2024, 2026)

  • Explore study findings

    Why a two-amino-acid breakdown product drew attention in 2026

    TB-500 is used here for the acetylated seven-amino-acid fragment corresponding to part of thymosin beta-4. A 2026 study asked whether a smaller molecule made during its breakdown could explain some effects attributed to the parent peptide.

    TB-5002 sources (2024, 2026)

  • Explore study findings

    What a rat Achilles study reported for its TB-500 group

    TB-500 commonly refers to a synthetic acetylated fragment of thymosin beta-4 made from seven amino acids. A July 2026 rat experiment used a reagent labeled TB-500 after surgical repair of the Achilles tendon.

    TB-5002 sources (2012, 2026)

  • Explore study findings

    Which molecule the 2026 HHS policy calls TB-500

    Department of Health and Human Services defined TB-500 acetate as the acetate form of an N-acetylated seven-amino-acid fragment of thymosin beta-4. The policy makes the chemical identity explicit because names used for research products can be ambiguous.

    TB-5003 sources (2026)

  • Check methods and identity

    What mass spectrometry detected as TB-500 broke down

    TB-500 is an acetylated seven-amino-acid fragment of thymosin beta-4. In an older 2024 study, researchers asked which shorter molecules appeared after it was broken down and whether those molecules could be measured separately.

    TB-5002 sources (2024, 2026)

  • Understand the science

    How a laboratory identified the acetylated fragment

    TB-500 can refer to a short acetylated fragment of thymosin beta-4. The name became associated with that identity in part through an older 2012 study of a product sold under the name. The scientists used high-resolution mass spectrometry to examine the material.

    TB-5001 source (2012)

  • Understand the science

    How to read a human eye trial cited alongside TB-500

    TB-500 generally refers to an acetylated seven-amino-acid fragment related to thymosin beta-4. An older human trial often discussed in the same research area investigated a specific eye formulation, RGN-259, whose active substance was synthetic full-length thymosin beta-4.

    TB-5002 sources (2012, 2015)

  • Check methods and identity

    What the current U.S. label means by excess abdominal fat

    Tesamorelin is a synthetic analogue of human growth hormone–releasing factor. It contains the 44-amino-acid sequence of that hormone and an added chemical group at the beginning. What does the approved indication mean when it describes a reduction in excess abdominal fat?

    Tesamorelin2 sources (2010, 2026)

  • Check methods and identity

    What the TRIUMPH trial is designed to measure about physical function

    Tesamorelin is a 44-residue growth hormone–releasing hormone analogue with a chemical modification at its starting end. It can stimulate the pituitary to release growth hormone.

    Tesamorelin2 sources (2026)

  • Check methods and identity

    What bioequivalence means in a comparison of tesamorelin formulations

    Tesamorelin is a chemically modified 44-residue analogue of growth hormone–releasing hormone. A report published in January 2026 compared how the newer Egrifta WR formulation and the original Egrifta formulation appeared in the blood of healthy adults.

    Tesamorelin2 sources (2026)

Browse by product

General topics

Articles from the Heritage Bio Labs research series, with links to the original sources. For research use only; not medical advice. Library index (JSON)